Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [ 11C] P943: A positron emission tomography study in Papio anubis

Synapse

Volumn 65, Issue 11, 2011, Pages 1119-1127

  Ridler, Khanum ^a   Plisson, Christophe ^a   Rabiner, Eugenii A ^a,b   Gunn, Roger N ^a,b,c   Easwaramoorthy, Balu ^d,e   Abi Dargham, Anissa ^d,e   Laruelle, Marc ^a,b,d   Slifstein, Mark ^d,e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Department of Psychiatry ^*  (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

5 HT 1B receptor; Endogenous competition; Fenfluramine; PET; Positron emission tomography; Serotonin

Indexed keywords

AMPHETAMINE; CARBON C 11 P943; CITALOPRAM; FENFLURAMINE; P 943; SB 616234S; SB 714786; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ENANTIOMER; IN VIVO STUDY; MALE; NONHUMAN; PAPIO ANUBIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; SENSITIVITY ANALYSIS; STEREOISOMERISM;

ANIMALS; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PAPIO ANUBIS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRROLIDINONES; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN;

EID: 80052391842     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20946     Document Type: Article

References (24)

1. Ashburner J, Friston K. 1997. Multimodal image coregistration and partitioning-A unified framework. Neuroimage 6: 209-217.
2. Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM. 2004. Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29: 847-859.
3. Bhagwagar Z, Ruf B, Gallezot J-D, Hu J, Pittman B, Krystal J, Nabulsi N, Neumeister A, Huang YH, Ding Y-S, Carson RE. 2008. Test-retest reliability of the novel PET radioligand [11C]-P943 as a measure of 5-HT1B receptor binding. Biol Psychiatry 63(184S):Abstract 578.
4. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ. 1997. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614-1623.
5. Burnham K, Anderson D. 1998. Model selection and inference: A practical information theoretic approach. New York: Springer. 353p.
6. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. 2010. Measuring drug occupancy in the absence of a reference region: The Lassen plot re-visited. J Cereb Blood Flow Metab 30: 46-50.
7. De Haes JIU, Harada N, Elsinga PH, Maguire RP, Tsukada H. 2006. Effect of fenfluramine-induced increases in serotonin release on [F-18]MPPF]binding: A continuous infusion PET study in conscious monkeys. Synapse 59: 18-26.
8. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, Zimmer L, Costes N, Mulligan R, Reutens D. 2006. Increased serotonin receptor availability in human sleep: Evidence from an [18F]MPPF PET study in narcolepsy. NeuroImage 30: 341-348.
9. Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, Farde L. 2010. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT1B-receptors in the primate brain. Synapse 64: 573-577.
10. Gallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, Kim S, Maguire RP, McCarthy T, Frost JJ, Huang Y, Ding YS, Carson RE. 2010. Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab Official J Int Soc Cereb Blood Flow Metab 30: 196-210.
11. Gobel H, Heinze A, Stolze H, Heinze-Kuhn K, Lindner V. 1999. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia 19: 676-683; discussion 626.
12. Helal C, Gunnar ABL, Sheng J, Jaynes-sobolov S, McCarthy T. 2006. 11C-labeled benzyl-lactam compounds and their use as imaging agents. An international patent search report. International Patent Application, WO 2006/075226 A1.
13. Laruelle M. 2000. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20: 423-451.
14. Nabulsi N, Huang Y, Weinzimmer D, Ropchan J, Frost JJ, McCarthy T, Carson RE, Ding YS. 2010. High-resolution imaging of brain 5-HT 1B receptors in the rhesus monkey using [11C]P943. Nuclear Med Biol 37: 205-214.
15. Nash MW, Sugden K, Huezo-Diaz P, Williamson R, Sterne A, Purcell S, Sham PC, Craig IW. 2005. Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. Am J Med Genet B Neuropsychiatr Genet 135B: 33-37.
16. Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. 2010. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab Official J Int Soc Cereb Blood Flow Metab 30: 1682-1706.
17. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, Takano A, Karlsson P, Gulyas B, Medd AM, Lee CM, Powell ME, Heys JR, Potts W, Seneca N, Mrzljak L, Farde L, Halldin C. 2008. C-11 AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 41: 1075-1085.
18. Scatchard G. 1949. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672.
19. Scott C, Langmead CJ, Clarke KL, Wyman P, Smith PW, Starr KR, Dawson LA, Price GW, Hagan JJ, Watson J. 2006. SB-616234-A (1-6-(cis-3, 5-dimethylpiperazin-1-yl)-2, 3-dihydro-5 methoxyindol-1-yl-1-2' methyl-4'-(5-methyl-1, 2, 3-oxadiazol-3-yl) biphenyl-4-yl methanone hydrochloride): A novel, potent and selective 5-HT1B receptor antagonist. Neuropharmacology 50: 984-990.
20. Smoller JW, Biederman J, Arbeitman L, Doyle AE, Fagerness J, Perlis RH, Sklar P, Faraone SV. 2006. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. Biol Psychiatry 59: 460-467.
21. Tomasi G, Nabulsi N, Weinzimmera D, Sandiego C, Gallezot JD, Wang E, McLean S, Huang Y, Ding Y, Carson RE. 2008. In vivo Scatchard analysis of bolus/infusion 5-HT1B studies with [C-11]P943: Comparison between SRTM and equilibrium methods. Neuroimage 41: T16-T16.
22. Varnas K, Hall H, Bonaventure P, Sedvall G. 2001. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res 915: 47-57.
23. Ward SE, Harrington FP, Gordon LJ, Hopley SC, Scott CM, Watson JM. 2005. Discovery of the first potent, selective 5-hydroxytryptamine(1D) receptor antagonist. J Med Chem 48: 3478-3480.
24. Zimmer L, Rbah L, Giacomelli F, Le Bars D, Renaud B. 2003. A reduced extracellular serotonin level increases the 5-HT1A PET ligand 18F-MPPF binding in the rat hippocampus. J Nucl Med Official Publ Soc Nucl Med 44: 1495-1501.